Docket No.: HYDR-P01-005
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Li et al.

Application No.: 10/509472 Confirmation No.: 6718

Filed: September 21, 2005 Art Unit: 1636

For: ELASTIN PREVENTS OCCLUSION OF BODY VESSELS BY VASCULAR SMOOTH MUSCLE CELLS Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information

as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. HYDR-P01-005.

Dated: 3/13/06

Respectfully submitted,

By _____

Melissa S. Rones, Ph.D.
Registration No.: 54,408
ROPES & GRAY LLP
One International Place
Boston, Massachusetts 02110-2624
(617) 951-7000
(617) 951-7050 (Fax)
Attorneys/Agents For Applicant

PTO/SB/92 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Application No. (if known): 10/509472 Attorney Docket No.: HYDR-P01-005

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on March 13, 2006 .
Date

Signature

Ginny Blundell
Typed or printed name of person signing Certificate

Registration Number, if applicable

(617) 951-7000
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS by Applicant – Form PTO/SB/08 (146 References)
References (BA-BS, CA-CM3)

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 6

Complete if Known	
Application Number	10/509472
Filing Date	September 21, 2005
First Named Inventor	Dean Y. Li
Art Unit	1636
Examiner Name	Not Yet Assigned
Attorney Docket Number	HYDR-P01-005

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	4,323,358	04-06-1982	Lentz et al.	
	AB*	4,352,887	10-05-1982	Reid et al.	
	AC*	4,553,974	11-19-1985	Dewanjee	
	AD*	4,739,762	04-26-1988	Palmaz	
	AE*	4,877,599	10-31-1989	Lees	
	AF*	4,960,423	10-02-1990	Smith	
	AG*	4,976,734	12-11-1990	Urry et al.	
	AH*	5,064,430	11-12-1991	Urry	
	AI*	5,336,256	08-09-1994	Urry	
	AJ*	5,591,224	01-07-1997	Schwartz et al.	
	AK*	5,595,571	01-21-1997	Jaffe et al.	
	AL*	5,628,785	05-13-1997	Schwartz et al.	
	AM*	5,650,282	07-22-1997	Keating et al.	
	AN*	5,716,394	02-10-1998	Bruchman et al.	
	AO*	5,720,777	02-24-1998	Jaffe et al.	
	AP*	5,726,153	03-10-1998	Lees et al.	
	AQ*	5,728,420	03-17-1998	Keogh	
	AR*	5,749,895	05-12-1998	Sawyer et al.	
	AS*	5,776,182	07-07-1998	Bruchman et al.	
	AT*	5,791,352	08-11-1998	Reich et al.	
	AU*	5,840,489	11-24-1998	Keating et al.	
	AV*	5,843,180	12-01-1998	Jaffe et al.	
	AW*	5,843,181	12-01-1998	Jaffe et al.	
	AX*	5,852,009	12-22-1998	Cerami et al.	
	AY*	5,855,620	01-05-1999	Bishopric et al.	
	AZ*	5,856,245	01-05-1999	Caldwell et al.	
	AA1*	5,858,662	01-12-1999	Keating et al.	
	AB1*	5,874,164	02-23-1999	Caldwell	
	AC1*	5,891,506	04-06-1999	Keogh	
	AD1*	5,891,558	04-06-1999	Bell et al.	
	AE1*	5,925,552	07-20-1999	Keogh et al.	
	AF1*	5,928,916	07-27-1999	Keogh	
	AG1*	5,945,319	08-31-1999	Keogh	
	AH1*	5,955,055	09-21-1999	Lees et al.	
	AI1*	5,972,890	10-26-1999	Lees et al.	
	AJ1*	5,990,379	11-23-1999	Gregory	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	BA	JP-59112909	06-29-1984			
	BB	JP-59112951	06-29-1984			
	BC	WO-90/07936	07-26-1990	Chiron Corporation		
	BD	WO-92/19195	11-12-1992	Brown University Research Foundation		

Examiner Signature		Date Considered	

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 6

Complete if Known	
Application Number	10/509472
Filing Date	September 21, 2005
First Named Inventor	Dean Y. Li
Art Unit	1636
Examiner Name	Not Yet Assigned
Attorney Docket Number	HYDR-P01-005

	BE	WO-92/22309	12-23-1992	Imperial Chemical Industries, PLC		
	BF	WO-94/25503	11-10-1994	Cytotherapeutics, Inc.		
	BG	WO-95/01203	01-12-1995	Cytotherapeutics, Inc.		
	BH	WO-95/05452	02-23-1995	Cytotherapeutics, Inc.		
	BI	WO-96/02286	02-01-1996	Cytotherapeutics, Inc.		
	BJ	WO-96/02646	02-01-1996	Cytotherapeutics, Inc.		
	BK	WO-96/40871	12-19-1996	Cytotherapeutics, Inc.		
	BL	WO-96/40959	12-19-1996	Cytotherapeutics, Inc.		
	BM	WO-97/12635	04-10-1997	Cytotherapeutics, Inc.		
	BN	WO-97/34998	09-25-1997	Human Genome Sciences, Inc.		
	BO	WO-98/01740	01-15-1998	University of Utah Research Foundation		
	BP	WO-98/05685	02-12-1998	Protein Specialities, LTD.		
	BQ	WO-99/03886	01-28-1999	The University of Sydney		
	BR	WO-99/45941	09-16-1999	MRS, LLC		
	BS	WO-99/53943	10-28-1999	Angio-Genix, Incorporated		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	CA	Adams et al., "Regulation of development and differentiation by the extracellular matrix," Development, 117:1183-1198, (1993).	
	CB	American Heart Association, *Heart and Stroke Facts: 1996 Statistical Supplement* (American Heart Association, Dallas, TX) (1996).	
	CC	Anders et al., "Murine Models of Renal Disease: Possibilities and Problems in Studies Using Mutant Mice," Exp. Nephrol., 8:181-193, (2000).	
	CD	Beck et al., "Vascular development: cellular and molecular regulation," FASEB, 11:365-373, (1997).	
	CE	Bloom, W. and Fawcett, D., "A Textbook of Histology", 10 Ed., pages 398-402 (Saunders, Philadelphia) (1975)	
	CF	Boyle et al., "Endothelium-independent Vasoconstricting and Vasodilating Actions of Halothane on Rat Mesenteric Resistance Blood Vessels," Anesthesiology, 82(1):221-235, (1995).	
	CG	Bradley, et al., "Modifying the Mouse: Design and Desire," Bio Tech., 10:534-539, (1992).	
	CH	Burn et al., "Developmental genetics of the heart," Curr. Opin. In Genetics and Development, 6:322-325, (1996).	
	CI	Carmeliet et al., "Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele," Nature, 380 (6573):435-439, (1996).	
	CJ	Cowan, K. et al., "Serine Elastase and Matrix Metalloproteinase (MMP) Inhibition Induced Pulmonary Artery (PA) Smooth Muscle Cell (SMC) Apoptosis Leading to Regression of Vascular Hypertrophy" Molecular Biology of the Cell 8 (Supp.) page 287A (1997)	

Examiner Signature		Date Considered	

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 6

Complete if Known	
Application Number	10/509472
Filing Date	September 21, 2005
First Named Inventor	Dean Y. Li
Art Unit	1636
Examiner Name	Not Yet Assigned
Attorney Docket Number	HYDR-P01-005

	CK	Curran et al., "The Elastin Gene Is Disrupted by a Translocation Associated with Supravalvular Aortic Stenosis," Cell, 73:159-168, (1993).	
	CL	Davis, Elaine, "Elastic Lamina Growth in the Developing Mouse Aorta," Journal of Histochemistry and Cytochemistry, 43(11):1115-1123, (1995).	
	CM	Deng et al., "Location of crossovers during gene targeting with insertion and replacement vectors," Mol. Cell. Biol. 13(4):2134-2140, (1993) (Abstract)	
	CN	Dietz et al., "Mutations in the human gene for fibrillin-1 (*FNB1)* in the Marfan syndrome and related disorders," Human Molecular Genetics, 4:1799-1809 (1995).	
	CO	Eck et al, "Gene-Based Therapy", Goodman & Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, pages 77-101 (1996)	
	CP	Ewart et al., "A human vascular disorder, supravalvular aortic stenosis, maps to chromosome 7," Proc. Natl. Acad. Sci., 90:3226-3230, (1993).	
	CQ	Ewart et al., "Hemizygosity at the elastin locus in a developmental disorder, Williams syndrome," Nature Genetics, 5:11-16 (1993).	
	CR	Ewart et al., "Supravalvular Aortic Stenosis Associated with a Deletion Disrupting the Elastin Gene," J. Clin. Invest., 93:1071-1077, (1994).	
	CS	Fazio et al., "Isolation and Characterization of Human Elastin cDNAs, and Age-Associated Variation in Elastin Gene Expression in Cultured Skin Fibroblasts," Laboratory Investigation, 58(3):270-277, (1988).	
	CT	Ferrara et al., "Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene," Nature, 380:439-442 (1996).	
	CU	Folkman et al., "Blood Vessel Formation: What Is Its Molecular Basis?," Cell, 87:1153-1155, (1996).	
	CV	Fong et al., "Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium," Nature, 376:66-70, (1995).	
	CW	Galis et al., "Increased Expression of Matrix Metalloproteinases and Matrix Degrading Activity in Vulnerable Regions of Human Atherosclerotic Plaques," J. Clin. Inv., 94:2493-2503, (1994).	
	CX	Gardner et al., "Deletion of Integrin $\alpha 1$ by Homologous Recombination Permits Normal Murine Development but Gives Rise to a Specific Deficit in Cell Adhesion," Dev. Biol. 175:301-313, (1996).	
	CY	George et al., "Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin," Development, 119:1079-1091, (1993).	
	CZ	Gibbons et al., "Molecular Therapies for Vascular Diseases," Science, 272:689-693, (1996).	
	CA1	Glagov, et al., "Compensatory enlargement of human atherosclerotic coronary arteries," New England Jour. of Med., 316:1371-1375, (1987).	
	CB1	Glukhova et al., "Phenotypic changes of Human Aortic Smooth Muscle Cells During Development and in the Adult Vessel", American Journal of Physiology, 261, pages 78-80 (1991)	
	CC1	Gumbiner, Barry, "Cell Adhesion: The Molecular Basis of Tissue Architecture and Morphogenesis," Cell, 84:345-357, (1996).	
	CD1	Hanahan, Douglas, "Signaling Vascular Morphogenesis and Maintenance," Science, 277:48-50, (1997).	
	CE1	Houdebine, Louis-Marie, "Production of pharmaceutical proteins from transgenic animals," Journal of Biotechnology, 34:269-287, (1994).	
	CF1	Hynes, Richard O., "Genetic analyses of cell-matrix interactions in development," Curr. Opin. Genet. Dev., 4:569-574 (1994).	
	CG1	Hynes, Richard, "Integrins: Versatility, Modulation, and Signaling in Cell Adhesion," Cell, 69:11-25, (1992).	
	CH1	Ito, et al., "Inhibitory effect of type 1 collagen gel containing α-elastin on proliferation and migration of vascular smooth muscle and endothelial cells," Cardiovascular Surgery, 5(2):176-183, (1997).	

Examiner Signature		Date Considered	

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 6

Complete if Known	
Application Number	10/509472
Filing Date	September 21, 2005
First Named Inventor	Dean Y. Li
Art Unit	1636
Examiner Name	Not Yet Assigned
Attorney Docket Number	HYDR-P01-005

	CI1	Katoh et al., "Growth and Differentiation of Smooth Muscle Cells During Vascular Development," Trends Cardiovasc. Med., 6(3):100-106 (1996).	
	CJ1	Kaye et al., "A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding," Proc. Natl. Acad. Sci., 87:6922-6926, (1990).	
	CK1	Keating, M.T., "Genetic Approaches to Cardiovascular Disease," Circulation, 92:142-147 (1995).	
	CL1	Keating, Mark, "Elastin and Vascular Disease," Trends in Cardiovascualr Medicine, 4(4):165-169, (1994).	
	CM1	Keating, Mark, "On the trail of genetic culprits in Williams syndrome," Cardiovasc. Res., 36:134-137, (1997).	
	CN1	Koyama et al., "Fibrillar Collagen Inhibits Arterial Smooth Muscle Proliferation through Regulation of Cdk2 Inhibitors," Cell, 87:1069-1078 (1996).	
	CO1	Langille et al., "Blood Flow Dynamics, Atherosclerosis and Bypass Graft Failure," Trends Cardiovasc. Med., 7(4):111-118 (1997).	
	CP1	Li et al., "Elastin is an essential determinant of arterial morphogenesis," Nature, 393:276-280, (1998).	
	CQ1	Li et al., "Elastin point mutations cause an obstructive vacular disease, supravalvular aortic stenosis," Human Molecular Genetics, 6(7):1021-1028, (1997).	
	CR1	Li et al., "Novel Arterial Pathology in Mice and Humans Hemizygous for Elastin," J. Clin. Inv., 102(10):1783-1787, (1998).	
	CS1	Lindahl et al., "Pericyte Loss and Microaneurysm Formation in PDGF-B-Deficient Mice," Science, 277:242-245 (1997).	
	CT1	Lohler et al., "Embryonic Lethal Mutation in Mouse Collagen I Gene Causes Rupture of Blood Vessels and Is Associated with Erythropoietic and Mesenchymal Cell Death," Cell, 38:597-607 (1984).	
	CU1	Machii et al., "Morphologic Features of the Normal Aortic Arch in Neonates, Infants, and Children Pertinent to Growth," Ann Thorac Surg, 64:511-515 (1997).	
	CV1	Mansour et al., "Disruption of the proto-oncogene *int-2* in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes," Nature, 336:348-352 (1988).	
	CW1	Maruyama et al., "Chronic hypoxic pulmonary hypertension in rats and increased elastolytic activity," Am. J. Physiol., 261:H1716-H1726 (1991).	
	CX1	Milnor, William R., "Principles of Hemodynamics in Cardiovascular Physioogy, Oxford University Press, 184-186 (1990).	
	CY1	Morris, Colleen, "Genetic aspects of supravalvular aortic stenosis," Curr. Opin. in Cardiology, 13:214-219, (1998),	
	CZ1	O'Connor et al., "Supravalvular Aortic Stenosis," Arch. Pathol. Lab Med., 109:179-185 (1985).	
	CA2	Ooyama et al., "Substratum-Bound Elastin Peptide Inhibits Aortic Smooth Muscle Cell Migration in Vitro," Arteriosclerosis, 7(6):593-598 (1987).	
	CB2	Owens, Gary, "Regulation of Differentiation of Vascular Smooth Muscle Cells," Physiol. Rev., 75(3):487-517 (1995).	
	CC2	Palmiter et al., "Metallothionein-Human GH Fusion Genes Stimulate Growth of Mice," Science, 222:809-814 (1983).	
	CD2	Parks et al., "Elastin," Advances in Molecular and Cell Biology, 6:133-181 (1993).	
	CE2	Perou, Maurice L., "Congenital Supravalvular Aortic Stenosis," Arch. Pathol., 71:113-126 (1961).	
	CF2	Perrin et al., "Developmental Regulation of Elastin Gene Expression," Crit. Rev. Eukaryot. Gene Exp., 7(1&2):1-10, (1997).	
	CG2	Prosser et al., "Regional Heterogeneity of Elastin and Collagen Gene Expression in Intralobar Arteries in Response to Hypoxic Pulmonary Hypertension as Demonstrated by *In Situ* Hybridization," Amer. J. Pathol., 135(6):1073-1088 (1989).	

Examiner Signature		Date Considered	

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 5 of 6

Complete if Known	
Application Number	10/509472
Filing Date	September 21, 2005
First Named Inventor	Dean Y. Li
Art Unit	1636
Examiner Name	Not Yet Assigned
Attorney Docket Number	HYDR-P01-005

	CH2	Pursel et al., "Expression and performance in transgenic pigs," J. Reprod. Fert., Suppl., 40:235-245 (1990).	
	CI2	Rabinovitch, Marlene, "Cell-Extracellular Matrix Interactions in the Ductus Arteriosus and Perinatal Pulmonary Circulation," Seminars in Perinatology, 20(6):531-541, (1996).	
	CJ2	Raju et al., "Primary Structures of Bovine Elastin a, b, and c Deduced from the Sequences of cDNA Clones," Journal of Biological Chemistry, 262(12):5755-5762, (1987).	
	CK2	Reitamo et al., "Interleukin 10 up-regulates elastin gene expression in vivo and in vitro at the transcriptional level," Biochem. Jour., 302:331-333, (1994).	
	CL2	Ross, Russell, "The pathogenesis of atherosclerosis: a perspective for the 1990s," Nature, 362:801-809 (1993).	
	CM2	Rudinger, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence, Pedptide Hormones, pages 1-7 (1976)	
	CN2	Saga et a., "Mice develop normally without tenascin," Genes Dev., 6:1821-1831 (1992).	
	CO2	Sato et al., "Distinct Roles of the Receptor Tyrosine Kinases Tie-1 and Tie-2 in Blood Vessel Formation", Letters to Nature, Vol. 376, pages 70-74 (1995)	
	CP2	Sauvage et al., "Aortic Elastin and Collagen Content and Synthesis in Two Strains of Rats with Different Susceptibilities to Rupture of the Internal Elastic Lamina," J. Vasc. Res., 34:126-136, (1997).	
	CQ2	Schwartz et al., "Developmental Mechanisms Underlying Pathology of Arteries," Physiol. Rev., 70(4):1177-1209 (1990).	
	CR2	Schwartz et al., "The Intima: Soil for Atherosclerosis and Restenosis," Cir. Res., 77:445-465 (1995).	
	CS2	Seamark, R.F., "Progress and Emerging Problems in Livestock Transgenesis: a Summary Perspective," Reprod. Fertil. Dev., 6:653-657, (1994).	
	CT2	Sechier et al., "Elastin gene mutations in transgenic mice," Ciba Foundation Symposium, 192:148-171 (1995).	
	CU2	Senior et al., "Chemotactic Activity of Elastin-derived Peptides," J. Clin. Inv., 66:859-862, (1980).	
	CV2	Senior et al., "Val-Gly-Val-Ala-Pro-Gly, a Repeating Peptide in Elastin, Is Chemotactic for Fibroblasts and Monocytes," The Journal of Cell Biology, 99:870-874 (1984).	
	CW2	Shalaby et al., "Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice," Nature, 376:62-66 (1995).	
	CX2	Skolnick et al., "From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era, TIBECH, Vol. 18, pages 34-39 ,2000	
	CY2	Suri et al., "Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis," Cell, 87:1171-1180 (1996).	
	CZ2	Tajima et al., "Modulation by elastin peptide VGVAPG of cell proliferation and elastin expression in human skin fibroblasts," Archives of Dermatological Research, 289(8):489-492, (1997).	
	CA3	Tajima, Shingo, "Correlation of Elastin Expression and Vascular Smooth Muscle Cell Proliferation *In Vitro*," Extracellular Matrix-Cell Interactions: Molecules to Diseases (Japan Scientific Societies Press) Pages 109-121 (1998).	
	CB3	Tassabehji et al., "An elastin gene mutation producing abnormal tropoelastin and abnormal elastic fibres in a patient with autosomal dominant cutis laxa," Human Molecular Genetics, 7(6):1021-1028, (1998).	
	CC3	Tassabehji et al., "Elastin: genomic structure and point mutations in patients with supravalvular aortic stenosis," Human Molecular Genetics, 6(7):1029-1036, (1997).	
	CD3	Terpin et al., "A biophysical and histological analysis of factors that lead to aortic rupture in normal and lathyritic turkeys," Can. J. Physiol. Pharmacol., 65:395-400 (1987).	
	CE3	Thomas et al., "Targeted disruption of the murine *int-1* proto-oncogene resulting in severe	

Examiner Signature		Date Considered	

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	6	of	6

Complete if Known	
Application Number	10/509472
Filing Date	September 21, 2005
First Named Inventor	Dean Y. Li
Art Unit	1636
Examiner Name	Not Yet Assigned
Attorney Docket Number	HYDR-P01-005

		abnormalities in midbrain and cerebellar development," Nature, 346:847-850 (1990).	
	CF3	Thompson, Robert W., "Basic science of abdominal aortic aneurysms: emerging therapeutic strategies for an unresolved clinical problem," Curr. Opin. Cardiol., 11:504-518 (1998).	
	CG3	Wolinsky et al., "A Lamellar Unit of A rtic Medial Structure and Function in Mammals," Circ. Res., 20:99-111 (1967).	
	CH3	Wu et al., "Delineation of the common critical region in Williams syndrome and clinical correlation of growth, heart defects, ethnicity, and parental origin," Am. J. Med. Genet., 78(1):82-89, (1998).	
	CI3	Wu et al., "Methods in Gene Biotechnology," Chapter 17, pages 339-365.	
	CJ3	Wydner et al., "Use of an Intron Length Polymorphism to Localize the Tropoelastin Gene to Mouse Chromosome 5 in a Region of Linkage Conservation with Human Chromosome 7," Genomics, (23):125-131, (1994).	
	CK3	Yamamoto et al., "Increase in Elastin Gene Expression and Protein Synthesis in Arterial Smooth Muscle Cells Derived From Patients with Moyamoya Disease," Stroke, 28(9):1733-1738, (1997).	
	CL3	Yang et al., "Embryonic mesodermal defects in $\alpha 5$ integrin-deficient mic," Development, 119:1093-1105 (1993).	
	CM3	Zheng et al., "Vitronectin is not essential for normal mammalian development and fertility," Proc. Natl., Acad. Sci. USA, 92:12426-12430 (1995).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	